//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
#Zasocitinib erreichte in einer direkten Phase-3-Studie zu #Psoriasis eine >2,5-fach höhere PASI-100-Rate als Deucravacitinib bei konstanter Sicherheit und einmal täglicher oraler Gabe www.ipharmacenter.com/post/takeda-... #nachrichten #pharma #gesundheitswesen #globalhealth #lifesciences
3h
www.ipharmacenter.com
Takeda reports that its investigational oral therapy Zasocitinib achieved markedly stronger outcomes than deucravacitinib in a head-to-head Phase 3 trial in adults with moderate to severe plaque psori...
Takeda's Zasocitinib achieved over 2.5 times the PASI 100 rate of deucravacitinib in a head‑to‑head Ph3 psoriasis trial | iPharmaCenter